Back

FASN Inhibition Resensitizes Chordoma to Radiotherapy by Targeting Adaptive Unsaturated Fatty Acid Metabolism

WEI, R.; Meng, Y.; Nasajpour, E.; Panovska, D.; Oft, H. C. M.; Xing, Y. L.; Lee, C. K.; Fernandez-Miranda, J. C.; Banu, M. A.; Zare, R. N.; Petritsch, C. K.

2026-05-14 cancer biology
10.64898/2026.05.11.724415 bioRxiv
Show abstract

SUMMARYChordoma, a rare malignant notochordal tumor of the skull base and spine, is typically resistant to chemotherapy and radiotherapy and exhibits aggressive local recurrence. Here we show that chordoma recurrence correlates with a coordinated upregulation of monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs), a low PFA/MUFA ratio and an adaptive, lipid peroxidation-resistant state that protects against DNA damage and cell death. Single-cell metabolic profiling identified a tumor subpopulation marked by a fatty acid biosynthesis-high state coupled to stemness. RT-tolerance was directly linked to elevated FASN and lipid droplet (LD) expansion, and MUFA-loading phenocopied RT-tolerance in chordoma cells. Mechanistically, LDs accumulated in response to RT via generation of ROS, and subsequent activation of ER-stress, SREBP1 and Fatty Acid Synthetase (FASN). DESI-MS showed that low-dose irradiation was sufficient to increase MUFAs early and build peroxidation resistant MUFA-LDs, whereas PUFA induction required a higher radiation dose. In a spatially defined manner in a patient-derived xenograft. Finally, in silico knockout and pharmacologic FASN blockade restored radiosensitivity and apoptosis in vitro and in vivo. Collectively, our result support a unifying model in which RT resistance in chordoma is shaped by an adaptive fatty acid metabolic program that buffers oxidative injury and increases survival of RT-resistant, stem-like tumor subpopulations. These findings further support FASN inhibition as a practical radiosensitization strategy for chordoma particulary where RT dose escalation is constrained by anatomy. KEYPOINTSO_LIRecurrent chordoma exhibits fatty acid-associated metabolic reprogramming. C_LIO_LIMUFA-associated lipid droplet accumulation is linked to radioresistance in chordoma cells. C_LIO_LITargeting FASN restores radiotherapy sensitivity of chordoma in vitro and in vivo. C_LI IMPORTANCE OF STUDYThis study underscores the clinical importance of targeting metabolic vulnerabilities to restore radiosensitivity in chordoma. By integrating transcriptomics, metabolomics, and in vitro and in vivo models, we identified adaptive fatty acid metabolic reprogramming as a central mechanism of RT resistance in chordoma. Recurrent tumors were characterized by coordinated enrichment of unsaturated fatty acids, especially monounsaturated fatty acids (MUFAs), together with a low PUFA/MUFA ratio and a lipid peroxidation-resistant state. Mechanistically, RT-tolerance chordoma cells exhibited a high-FASN state driven by activation of the ROS-ER stress-PERK/SREBP1/FASN axis, leading to intracellular lipid droplet expansion. Importantly, genetic and pharmacologic inhibition of FASN restored radiosensitivity and enhanced apoptosis in both in vitro and in vivo models, suggesting a translatable therapeutic strategy. Together, these findings link adaptive metabolic reprogramming to RT resistance and support new therapeutic approaches for chordoma management.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 15%
12.3%
2
Cancer Research
116 papers in training set
Top 0.1%
12.3%
3
Clinical Cancer Research
58 papers in training set
Top 0.1%
12.1%
4
Cell Reports
1338 papers in training set
Top 3%
9.9%
5
Neuro-Oncology
30 papers in training set
Top 0.2%
4.8%
50% of probability mass above
6
Cell Reports Medicine
140 papers in training set
Top 1%
3.6%
7
Cancer Discovery
61 papers in training set
Top 0.6%
3.5%
8
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.4%
9
Cancer Cell
38 papers in training set
Top 0.7%
2.3%
10
Oncogene
76 papers in training set
Top 0.8%
2.0%
11
eLife
5422 papers in training set
Top 39%
1.9%
12
Cancer Letters
32 papers in training set
Top 0.2%
1.9%
13
Genome Medicine
154 papers in training set
Top 5%
1.7%
14
JCI Insight
241 papers in training set
Top 4%
1.7%
15
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 34%
1.6%
16
Nature Cancer
35 papers in training set
Top 0.9%
1.5%
17
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.5%
18
Cancer Research Communications
46 papers in training set
Top 0.7%
1.2%
19
The EMBO Journal
267 papers in training set
Top 3%
1.2%
20
Science Advances
1098 papers in training set
Top 24%
1.2%
21
npj Precision Oncology
48 papers in training set
Top 0.9%
1.2%
22
Scientific Reports
3102 papers in training set
Top 69%
0.9%
23
Cell Systems
167 papers in training set
Top 12%
0.8%
24
Developmental Cell
168 papers in training set
Top 12%
0.7%
25
Molecular Cancer
14 papers in training set
Top 1%
0.6%
26
Journal of Bone and Mineral Research
32 papers in training set
Top 0.5%
0.6%
27
Breast Cancer Research
32 papers in training set
Top 0.6%
0.6%
28
Genome Biology
555 papers in training set
Top 9%
0.6%
29
ACS Central Science
66 papers in training set
Top 3%
0.6%